Guidance particularly addresses the value of ultrasound in patient-provider shared decision-making in management of care.

Low patient satisfaction in psoriasis and psoriatic arthritis for clinicians and treatment is tied to need for better ...

Many patients with rheumatic diseases refrain from telling their doctors about all physical and emotional symptoms they’re ...

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the completion of the dosing and initial follow-up period for ...

Global Healthy Living Foundation has 12 posters and Polymyalygia Rheumataca, Psoriasis and RA Research at American College of ...

The following is a summary of “Association between depression and anxiety and inability to achieve remission in rheumatoid ...

an investigational Nanobody® designed to treat inflammatory disease, in patients with active psoriatic arthritis (PsA). PsA ...

MoonLake Immunotherapeutics (MLTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday.

Similar percentages of patients with PsA receiving secukinumab vs adalimumab achieved an ACR20 response at 12 weeks.

Sonelokimab has already shown promising outcomes, with robust clinical efficacy observed across key psoriatic arthritis disease domains. The Phase 3 IZAR program is therefore an exciting ...

Sonelokimab has already shown promising outcomes, with robust clinical efficacy observed across key psoriatic arthritis disease domains. The Phase 3 IZAR program is therefore an exciting opportunity ...